News & Media

Bioscience Association Announces Kim Kline as New President

Kim.jpg (165 KB)

Kline,who has been serving as interim president for the past five months, is well known to BAM members and partnersfor her work as the association’s director of training anddevelopment. The Board of Directors said Kline has worked tirelessly to move BAM forward and advocate for the industry during a profound time of disruption brought on by COVID-19.


“The past year has highlighted the importance of science and research and the need for industry to adapt in real time. Kim’s leadership, commitment and creativity has helped us navigate and thrive during these unprecedented times,” said James Schellenberg, Board chair and CEO of Cubresa. “The Board is excited to continue to work with Kim on raising Manitoba’s profile as a global leader in the bioscience industry.”


Kline said there is a number of continuing successes that BAM can build upon – most notably Manitoba’s emergence as a national leader in medicaments. With $2.4B in exports in 2019, medicaments are now the province’s top export. Manitoba’s growing pharmaceutical manufacturing sector has moved into second spot in the country behind only Ontario.


“Our bioscience community is one that works towards solutions and our Health biotech companies have been at the forefront of our efforts to tackle the challenges created by COVID-19,” Kline said. “While human health has been very much top of mind this past year, our Ag biotech and Clean biotech sectors are also hard at work developing new products and supply chains that address our community’s needs. I’m extremely proud to be part of this sector and working with the bioscience companies that will lead our economic recovery and position us well for the future.”






BAM enables commercial success for Manitoba’s bioscience companies by acting as a catalyst for innovation, by expanding the sector’s skills and workforce development, and by leading with one unified voice to create local and global engagement. The organization is focused on Health biotech, Ag biotech, and Clean biotech. The sector includes 700 companies and organizations generating $10.4B in total sales annually and contributing $8.3B to Manitoba’s GDP (direct and indirect).